Company Overview and News

Pernod Ricard (PDRDY) Q3 FY18 Sales Call - Slideshow

3h seekingalpha
The following slide deck was published by Pernod Ricard S.A. ADR in conjunction with this event.
Upvote Downvote

What's Hurting AB InBev (BUD) Stock Price After a Solid Q4?

2018-04-09 zacks
Anheuser-Busch InBev SA/NV (BUD - Free Report) , alias AB InBev, depicted great strength in fourth-quarter 2017, which was clear from the top- and bottom-line beat after dismal trends in the past. Though this turnaround was a welcome sign, the company’s commentary on soft results, anticipated in the first quarter of 2018, has kept investors’ enthusiasm at bay. Consequently, shares of AB InBev lost 5.
Upvote Downvote

Tipsy Profits: Whiskey & Spirits ETF

2018-04-06 seekingalpha
Welcome to the first ETF to provide diversified exposure to the global whiskey and spirits industry.
Upvote Downvote

Investors scope out potential European wins from U.S.-China frictions

2018-04-05 reuters
LONDON (Reuters) - Nobody wins a trade war, International Monetary Fund chief Christine Lagarde said in March. But for some European companies, a bit of friction couldn’t hurt.
Upvote Downvote

Flash - Cuban rum and the end run around the US blockade - France 24

2018-04-04 france24
Cuba's signature rum, Havana Club, competes with the best known brands in the world even though it cannot be sold in the largest rum-consuming market.
Upvote Downvote

7 Consumer ETFs to Play the Big ‘Tax Return Spending Spree’

2018-03-28 investorplace
By now, it should be old news that Congress passed a massive tax cut at the end of last year. But amid all the paperwork and drudgery of filing your actual tax returns this spring, you may have forgotten what that means for the broader U.S. economy.
Upvote Downvote

Secoo's (SECO) CEO Richard Rixue Li on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Secoo Holding Limited (NASDAQ:SECO) Q4 2017 Results Earnings Conference Call March 22, 2018 8:00 AM ET
Upvote Downvote

The alcohol industry gave the government money to prove moderate drinking is safe

2018-03-21 cnbc
Over the weekend, the New York Times published a bombshell report on alarming ties between the alcohol industry and the National Institutes of Health. Specifically, five alcohol companies helped fund — and potentially shaped the design of — a 7,800-person randomized control trial overseen by the National Institute on Alcohol Abuse and Alcoholism, a center at the NIH. The trial is supposed to answer the long-simmering question of whether moderate drinking truly reduces the risk of cardiovascular disease.
Upvote Downvote

Tequila and Mezcal Are So Hot in U.S., Even Vodka Makers Want In - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Europe's drinks sector tells EU it will offer more product info

2018-03-12 reuters
BRUSSELS (Reuters) - Europe’s drinks sector announced plans on Monday to inform consumers more about the energy content and ingredients in beer, wine and spirits in a self-policing move, but critics said much of this information would only be available online.
Upvote Downvote

Should I worry about EU Trump Trade Tariffs? - Bloomberg

2018-03-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Europe's Bourbon Retaliation May Hurt Some of Its Own Companies - Bloomberg

2018-03-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Officer’s Choice maker Allied Blenders revives IPO plan, eyes year-end launch

2018-03-06 livemint
Bengaluru: Allied Blenders and Distillers Pvt. Ltd (ABD), India’s third largest liquor company, is reviving plans to go public and aims to launch its share offering by the end of 2018 at a rough valuation of around $1.8 billion, a top company executive said.
Upvote Downvote

The tough monkey to get off your back

2018-02-28 bworldonline
I TRIED my first Monkey 47 gin tonic in Singapore a few years back, and despite a rather stiff price tag of around SG$18/cocktail (over P700), I really enjoyed this incredibly grapefruit-driven and flavor-rich herbaceous gin. If you follow my columns, you know I am not a “neat” gin or “on the rocks” gin kind of drinker, but one who is more appreciative of gin in the context of the unsubstitutable gin tonic mix.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...